PTBP1 and acute lymphoblastic leukemia: In the light of our finding that PTBP1 knockdown increases CD19 intron 2 retention and thereby reduces CD19 epitope presentation, previous treatments with imatinib may have negative impact on the subsequent response to the CART-19 therapy in a subset of Ph+ B-ALL patients.